NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
Clinical Trials
15 trialsNCT06297629 2026-02-24
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT06868238 2026-02-18
Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)
University of Florida
Phase 2 Withdrawn
NCT05487859 2026-02-17
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT06501989 2026-02-11
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Phase 2 Withdrawn
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT04285268 2026-01-30
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT06012929 2026-01-26
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Withdrawn
NCT05846724 2026-01-22
PULSAR
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase 2 Withdrawn
NCT06967987 2026-01-21
BEMAFLOT
Institut Cancerologie de l'Ouest
Phase 2 Withdrawn
NCT06646016 2025-12-26
EPIC
Therakos LLC
Phase 2 Withdrawn
NCT07283848 2025-12-26
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
NCT06613516 2025-12-24
CaptAin
Imperial College London
Phase 2 Withdrawn